글로벌 진통제 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

진통제 시장 분석

글로벌 진통제 시장은 관절염, 암, 신경병성 통증과 같은 만성 질환의 유병률 증가와 수술이나 외상 후 통증 관리 솔루션에 대한 필요성 증가에 힘입어 상당한 성장을 경험하고 있습니다. 일반적으로 진통제로 알려진 진통제에는 아세트아미노펜(파라세타몰), 비스테로이드성 항염제(NSAID), 오피오이드 , 통증 완화를 목표로 하는 복합 약물과 같은 다양한 약물이 포함됩니다. 이 시장은 통증 관리가 필요한 상태에 더 취약한 노인 인구의 증가와 일반 의약품(OTC) 진통제의 채택 증가로 인해 강화되고 있습니다. 그러나 이 시장은 오피오이드 위기와 같은 어려움에 직면해 있으며, 이로 인해 여러 국가에서 엄격한 규제 조치와 오피오이드 처방 감소가 이루어졌습니다. 그럼에도 불구하고 비오피오이드 진통제와 지속 방출 진통제와 같은 새로운 제형에 대한 수요는 여전히 높으며, 특히 시장을 지배하는 북미와 같은 지역에서 그렇습니다. 아시아 태평양의 신흥 시장도 가처분 소득 증가, 의료 인프라 개선, 통증 관리 요법 에 대한 인식 증가로 인해 급속한 성장을 목격하고 있습니다 . 주요 제약 회사는 이 분야에서 혁신을 계속하고 있으며, 급성 및 만성 통증을 모두 해결하는 고급 진통제를 개발하여 시장 확장에 기여하고 있습니다.

진통제 시장 규모

글로벌 진통제 시장 규모는 2023년에 537억 2천만 달러로 평가되었으며, 2031년까지 775억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 4.69%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

진통제 시장 동향

“ 비오피오이드 진통제 채택 증가”

글로벌 진통제 시장은 만성 질환의 유병률 증가와 통증 관리 솔루션에 대한 수요 증가에 힘입어 꾸준한 성장을 보이고 있습니다. 이 시장에서 주목할 만한 추세는 오피오이드 중독과 관련된 규제 제한에 대한 우려가 커지면서 비오피오이드 진통제로의 전환입니다. 예를 들어, 이부프로펜과 아세트아미노펜과 같은 비스테로이드성 항염제(NSAID)는 통증 치료를 위한 보다 안전한 대안으로 주목을 받고 있습니다. Heron Therapeutics가 2021년에 출시한 ZYNRELEF는 수술 후 진통을 위해 설계된 비오피오이드 지속 방출 제품으로 최대 72시간 동안 효과적인 통증 완화 효과를 제공합니다. 이러한 변화는 경미하거나 중간 정도의 통증을 관리하는 데 소비자가 더 쉽게 접근하고 선호하는 일반 의약품(OTC) 진통제에 대한 관심이 높아지면서 뒷받침됩니다. 보다 안전하고 효과적인 통증 관리 솔루션에 대한 수요가 증가함에 따라 제약 회사는 혁신을 추진하여 글로벌 진통제 시장을 확대하고 있습니다.

보고서 범위 및 진통제 시장 세분화  

Analgesics Market Definition

Analgesics, commonly known as painkillers, are medications designed to relieve pain without causing a loss of consciousness. They work by reducing or blocking the body's pain signals and are used to treat a wide range of pain, from mild discomfort to severe pain associated with surgery, injury, or chronic conditions such as arthritis. 

Analgesics Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases significantly contributes to the demand for analgesics, as conditions like arthritis, cancer, and neuropathic pain require effective pain management solutions. According to the World Health Organization (WHO), approximately 1.5 billion people globally suffer from chronic pain, with arthritis affecting over 350 million individuals. As these conditions often result in persistent pain, patients seek analgesic treatments to improve their quality of life and manage their symptoms effectively. For instance, the American Cancer Society reports that about 50-90% of cancer patients experience pain at some point in their illness, highlighting the critical need for analgesics in oncology. This growing burden of chronic diseases is a key driver of the analgesics market, as healthcare providers and patients increasingly rely on both prescription and over-the-counter medications to address pain-related challenges effectively. The rising demand for effective pain management solutions continues to shape the landscape of the global analgesics market.

• Growing Awareness and Demand for Effective Pain Management

Growing awareness and demand for effective pain management are significantly influencing the analgesics market, as both healthcare providers and patients increasingly recognize the importance of addressing pain comprehensively in acute and chronic situations. According to the International Association for the Study of Pain, approximately 20% of adults worldwide experience chronic pain, highlighting the critical need for effective pain management strategies. As a result, healthcare systems are placing greater emphasis on pain relief protocols, with studies showing that effective pain management can improve patient outcomes and quality of life. Such recognition of pain as a significant public health issue is leading to a higher adoption rate of analgesics in clinical settings, encouraging pharmaceutical companies to innovate and expand their pain management product offerings. As the focus on pain management continues to grow, it serves as a vital driver of the global analgesics market.

Opportunities

• Increasing Research and Development on Novel Therapies

Research and development of novel therapies in the analgesics market present a substantial opportunity for introducing innovative pain relief options, particularly through the exploration of biologics and cannabinoids. As our understanding of pain mechanisms deepens, researchers are identifying new molecular targets that can be harnessed for pain management. For instance, the investigation of cannabinoids, such as CBD (cannabidiol), has shown promising results in clinical studies for treating various pain conditions, including neuropathic pain and chronic inflammation, due to their analgesic and anti-inflammatory properties. Additionally, biologics such as monoclonal antibodies targeting specific pain pathways have emerged as potential alternatives to traditional analgesics, offering new hope for patients with chronic pain who do not respond to conventional treatments. The ongoing research into these novel therapies broadens the therapeutic landscape and addresses the critical need for safer and more effective pain management solutions. As these innovative therapies move closer to clinical application, they are likely to transform the analgesics market, presenting significant opportunities for pharmaceutical companies to develop and commercialize new pain relief options that meet patient needs.

• Increasing Advancements in Drug Formulations

Advancements in drug formulations represent a significant opportunity in the analgesics market, particularly through innovations in drug delivery systems that enhance effectiveness and convenience for patients. Technologies such as transdermal patches and extended-release formulations allow for sustained pain relief with improved patient compliance. Additionally, combination therapies that integrate multiple analgesic agents can provide synergistic effects, enhancing pain relief while potentially lowering the dosage of individual medications, thus reducing side effects. The development of such innovative formulations addresses the challenges of adherence and aligns with the increasing demand for more efficient pain management solutions. As patients and healthcare providers seek safer and more effective analgesic options, these advancements pave the way for expanded market opportunities, making it essential for pharmaceutical companies to invest in research and development in this area.

Restraints/Challenges

• Regulatory Restrictions for Opioid-Based Products

Regulatory restrictions pose a significant challenge in the analgesics market, especially for opioid-based products, as stringent regulations aim to combat concerns related to abuse and addiction. For instance, the U.S. Food and Drug Administration (FDA) has implemented comprehensive guidelines that dictate the prescribing and dispensing of opioids, including risk evaluation and mitigation strategies (REMS) to ensure their safe use. These regulations require healthcare providers to undergo specific training, patients to be closely monitored, and detailed documentation for prescriptions, which can create barriers for patients who genuinely need these medications for pain management. This regulatory environment can lead to decreased availability of effective pain relief options, impacting patient care and satisfaction while fostering a climate of caution that may further stigmatize the use of opioids in legitimate medical contexts.

• Adverse Effects and Tolerability Issues

Adverse effects and tolerability issues present a significant challenge in the analgesics market, as many pain relief medications are associated with a range of side effects that can limit their use and effectiveness. For instance, non-steroidal anti-inflammatory drugs (NSAIDs), commonly prescribed for pain management, have been linked to gastrointestinal complications, such as ulcers and bleeding, particularly in long-term users. Similarly, opioids, while effective for managing severe pain, carry the risk of addiction and the development of tolerance, necessitating higher doses over time to achieve the same effect. This risk has led to increased scrutiny and caution in prescribing practices, making patients hesitant to use opioids even when needed for pain management. Such adverse effects can significantly affect patient compliance and satisfaction, as individuals may abandon effective pain management strategies due to fears of side effects, ultimately complicating their pain management journeys and creating barriers to optimal care.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Analgesics Market Scope

The market is segmented on the basis of pain type, drug class, type, application, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Pain Type

• Acute
• Chronic

Drug Class

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Opioids
  • Morphine
  • Fentanyl
  • Codiene
  • Methadone
  • Meperidine
  • Oxycodone
  • Tramadol
  • Dextromethorphan
  • Buprenorphine
  • Others
• Salicylates
• Others

Type

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

Application

• Musculoskeletal Pain
• Surgical and Trauma-Related Pain
• Cancer Pain
• Neuropathic Pain
• Migraines
• Obstetrical Pain
• Fibromyalgia
• Pain Due to Burns
• Dental/Facial Pain
• Pediatric Pain
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Analgesics Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, pain type, drug class, type, application, route of administration, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the analgesics market in both market share and revenue and is expected to maintain its dominance throughout the forecast period. This is attributed to the increasing incidence of chronic and acute pain, alongside rising healthcare spending, which will drive market growth in the region. Furthermore, the strong presence of key industry players and the growing adoption of advanced technologies will further accelerate market expansion.

Asia-Pacific is anticipated to experience the fastest growth in the analgesics market during the forecast period of 2024-2031, driven by increasing disposable income levels, which are boosting healthcare access and spending. Additionally, the ongoing development and modernization of healthcare infrastructure across key countries in the region is enhancing the availability of medical treatments. The rising number of generic drug manufacturers is also contributing to more affordable pain management solutions, further accelerating market growth in Asia-Pacific. This combination of factors positions the region for robust expansion in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Analgesics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Analgesics Market Leaders Operating in the Market Are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (아일랜드)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GSK plc (영국)
• 노바티스 AG(스위스)
• 머크앤코(미국)
• 아스트라제네카(영국)
• 존슨앤존슨 서비스 주식회사(미국)
• 히크마 제약(영국)
• Dr. Reddy's Laboratories Ltd. (인도)
• 루팡(인도)
• Fresenius Kabi AG(독일)
• Aurobindo Pharma(인도)
• 시플라(미국)
• Bausch Health Companies Inc. (캐나다)
• Amneal Pharmaceuticals LLC. (미국)
• Apotex Inc. (캐나다)
• 릴리(미국)

진통제 시장의 최신 동향

• 2021년 7월, 미국 기업인 Heron Therapeutics Inc.는 족지절제술, 사타구니 탈장 수술 또는 전체 무릎 교체 수술 후 최대 72시간 동안 수술 후 통증 완화를 제공하도록 설계된 지속 방출 제품인 ZYNRELEF를 출시했습니다. 이 제품은 연조직 및 관절 주위 적용을 타겟으로 합니다.
• 2021년 6월, Bayer는 일반의약품(OTC) 건강 제품에 대한 접근성을 높이기 위해 Consumer Health 사업부를 출범시켜 인도 시장에서 입지를 강화했습니다. 이러한 움직임은 인도와 같은 주요 신흥 시장에서 Consumer Health 포트폴리오를 확장하려는 Bayer의 전략을 지원합니다.
• 2021년 1월, Eli Lilly & Co.는 일본의 Asahi Kasei Pharma와 라이선스 계약을 체결하여 미국 기반 회사가 Asahi Kasei의 혁신적인 치료법을 개발하고 상용화할 수 있도록 했습니다. 이 파트너십은 핵심 치료 분야에서 치료법을 발전시켜 전 세계 환자에게 혜택을 제공하는 데 중점을 두고 있습니다.
• 2021년 1월, 파이저는 미국 의료 개선 기업인 프리미어와 파트너십을 맺어 다양한 환자 치료 개입을 위한 즉각적이고 장기적인 약물 요구 사항을 해결하는 것을 목표로 의료 종사자들에게 필수적인 5가지 약물을 제공했습니다.
• 2020년 5월, 캘리포니아에 본사를 둔 Assertio Therapeutics, Inc.는 펜실베이니아에 본사를 둔 Zyla Life Sciences와 합병하여 신경학, 염증 및 통증 관리 제품에 중점을 둔 확장 중인 상업용 제약 회사를 형성했습니다.

SKU-53388